Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Wednesday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Brooklyn ImmunoTherapeutics stock opened at $2.06 on Wednesday. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The firm has a 50-day moving average of $2.20 and a two-hundred day moving average of $1.85. The stock has a market cap of $121.18 million, a price-to-earnings ratio of -0.91 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.